These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 21040410)

  • 1. Efficacy of switching to telbivudine in chronic hepatitis B patients treated previously with lamivudine.
    Safadi R; Xie Q; Chen Y; Yin YK; Wei L; Hwang SG; Zuckerman E; Jia JD; Lopez P
    Liver Int; 2011 May; 31(5):667-75. PubMed ID: 21040410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B.
    Gane EJ; Wang Y; Liaw YF; Hou J; Thongsawat S; Wan M; Moon YM; Jia J; Chao YC; Niu J; Leung N; Samuel D; Hsu CW; Bao W; Lopez P; Avila C
    Liver Int; 2011 May; 31(5):676-84. PubMed ID: 21457439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B.
    Lai CL; Leung N; Teo EK; Tong M; Wong F; Hann HW; Han S; Poynard T; Myers M; Chao G; Lloyd D; Brown NA;
    Gastroenterology; 2005 Aug; 129(2):528-36. PubMed ID: 16083710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telbivudine versus lamivudine in patients with chronic hepatitis B.
    Lai CL; Gane E; Liaw YF; Hsu CW; Thongsawat S; Wang Y; Chen Y; Heathcote EJ; Rasenack J; Bzowej N; Naoumov NV; Di Bisceglie AM; Zeuzem S; Moon YM; Goodman Z; Chao G; Constance BF; Brown NA;
    N Engl J Med; 2007 Dec; 357(25):2576-88. PubMed ID: 18094378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B.
    Liaw YF; Gane E; Leung N; Zeuzem S; Wang Y; Lai CL; Heathcote EJ; Manns M; Bzowej N; Niu J; Han SH; Hwang SG; Cakaloglu Y; Tong MJ; Papatheodoridis G; Chen Y; Brown NA; Albanis E; Galil K; Naoumov NV;
    Gastroenterology; 2009 Feb; 136(2):486-95. PubMed ID: 19027013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients.
    Zheng MH; Shi KQ; Dai ZJ; Ye C; Chen YP
    Clin Ther; 2010 Apr; 32(4):649-58. PubMed ID: 20435234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naïve patients with HBV-related decompensated cirrhosis.
    Chan HL; Chen YC; Gane EJ; Sarin SK; Suh DJ; Piratvisuth T; Prabhakar B; Hwang SG; Choudhuri G; Safadi R; Tanwandee T; Chutaputti A; Yurdaydin C; Bao W; Avila C; Trylesinski A
    J Viral Hepat; 2012 Oct; 19(10):732-43. PubMed ID: 22967105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial.
    Hou J; Yin YK; Xu D; Tan D; Niu J; Zhou X; Wang Y; Zhu L; He Y; Ren H; Wan M; Chen C; Wu S; Chen Y; Xu J; Wang Q; Wei L; Chao G; Constance BF; Harb G; Brown NA; Jia J
    Hepatology; 2008 Feb; 47(2):447-54. PubMed ID: 18080339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The efficacy and safety of telbivudine in korean patients with chronic hepatitis B].
    Moon YM; Hwang SG; Kim BS; Rim KS; Cho M; Kim DJ; Han JY; Kim YS; Choi HS; Ahn SH
    Korean J Hepatol; 2007 Dec; 13(4):503-12. PubMed ID: 18159148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of telbivudine and entecavir for chronic hepatitis B in real-world clinical practice.
    Tsai MC; Lee CM; Chiu KW; Hung CH; Tung WC; Chen CH; Tseng PL; Chang KC; Wang JH; Lu SN; Yen YH; Hu TH
    J Antimicrob Chemother; 2012 Mar; 67(3):696-9. PubMed ID: 22174039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of switching to telbivudine plus adefovir in suboptimal responders to lamivudine plus adefovir.
    Park H; Park JY; Kim SU; Kim DY; Han KH; Chon CY; Ahn SH
    World J Gastroenterol; 2013; 19(43):7671-9. PubMed ID: 24431895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Telbivudine plus adefovir therapy for chronic hepatitis B patients with virological breakthrough or genotypic resistance to telbivudine.
    Zhang Y; Lian JQ; Li Y; Wang JP; Huang CX; Bai XF; Wang JP
    Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):814-9. PubMed ID: 23406845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B.
    Fung S; Kwan P; Fabri M; Horban A; Pelemis M; Hann HW; Gurel S; Caruntu FA; Flaherty JF; Massetto B; Dinh P; Corsa A; Subramanian GM; McHutchison JG; Husa P; Gane E
    Gastroenterology; 2014 Apr; 146(4):980-8. PubMed ID: 24368224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy.
    Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI
    J Gastroenterol Hepatol; 2010 Aug; 25(8):1374-80. PubMed ID: 20659226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients.
    Suzuki F; Toyoda J; Katano Y; Sata M; Moriyama M; Imazeki F; Kage M; Seriu T; Omata M; Kumada H
    J Gastroenterol Hepatol; 2008 Sep; 23(9):1320-6. PubMed ID: 18554238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial.
    Chan HL; Heathcote EJ; Marcellin P; Lai CL; Cho M; Moon YM; Chao YC; Myers RP; Minuk GY; Jeffers L; Sievert W; Bzowej N; Harb G; Kaiser R; Qiao XJ; Brown NA;
    Ann Intern Med; 2007 Dec; 147(11):745-54. PubMed ID: 17909201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Forty-eight-week retrospective study of telbivudine and lamivudine treatment in patients with hepatitis B-related cirrhosis.
    Han Z; Shi Y; Zhu J; Chen Y; Yin F; Xia L; Luo G; Gao Z; Liu J; Jia G; Li C; Zhou X; Han Y
    J Viral Hepat; 2013 Apr; 20 Suppl 1():58-64. PubMed ID: 23458526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of telbivudine therapy in liver failure patients with chronic hepatitis B virus infection.
    Wang L; Chen H; Fan C; Gong Z
    J Med Virol; 2013 Nov; 85(11):1907-12. PubMed ID: 23852947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B.
    Sherman M; Yurdaydin C; Sollano J; Silva M; Liaw YF; Cianciara J; Boron-Kaczmarska A; Martin P; Goodman Z; Colonno R; Cross A; Denisky G; Kreter B; Hindes R;
    Gastroenterology; 2006 Jun; 130(7):2039-49. PubMed ID: 16762627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telbivudine for the management of chronic hepatitis B virus infection.
    Matthews SJ
    Clin Ther; 2007 Dec; 29(12):2635-53. PubMed ID: 18201580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.